Generate Biomedicines, Inc.
GENB
Positions held
Your positionsGENB isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Generate Biomedicines operates in the biotechnology sector, which is poised for growth as advancements in personalized medicine and gene therapies continue to attract investment and innovation.
- The company's market cap stands at approximately $1.77 billion, indicating significant investor interest.
- Despite recent challenges, the target mean price for GENB is set at $27.0, suggesting potential upside from current levels.
- The company's revenue has declined by 13% compared to the prior quarter, dropping from $7.2M to $6.3M.
- Operating margin has significantly compressed to -1134.2%, reflecting ongoing financial struggles.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.80B | Enterprise value | $1.40B | Trailing P/E | — | Forward P/E | -6.14 |
| PEG | — | Price / book | 3.94 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | -37.7% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -11.3% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.14 |
| Current ratio | 8.30 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $27.00 |
| 52w high | $22.67 | 52w low | $11.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $6.3M | $7.2M | $10.1M | $8.8M |
| Op margin | -1134.2% | -887.5% | -593.8% | -546.1% |
| Net income | -$67.3M | -$61.4M | -$52.4M | -$41.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$71.6M | -$64.1M | -$60.1M | -$48.2M |
- Revenue -13% vs prior quarter ($6.3M vs $7.2M).
- Operating margin compressed to -1134.2%.
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $31.9M | $20.5M |
| Op margin | -737.0% | -962.6% |
| Net income | -$203M | -$174M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$235M | -$197M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
2026-09-08 · AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
2026-09-08 · Generate Biomedicines Inc. to Participate in September Investor Conferences
2026-09-07 · How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
2026-08-28 · Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
2026-08-27 · EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
2026-08-27 · Cathie Wood Sends a $20 Million Signal on Broadcom Stock
2026-08-26 · Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
2026-08-25 · Generate Biomedicines stock jumps as post-IPO lock-up set to expire
2026-08-18 · Nvidia Holds More Than 122 Million Shares of SPCX Stock After Q2. Barchart Data Shows It’s Making a High-Upside Bet.
2026-08-17 · Two Positions Make Up 80% of Nvidia's $63.4 Billion Portfolio
2026-08-17 · Nvidia Discloses Multi-Billion-Dollar Stakes in Intel, SpaceX in Filing
Price (daily)
Full chart · RSI · MACD · patterns